Patients and Medical
Medical Affairs & Social Media: A Brave New World
A great majority of healthcare providers now use social media platforms. Medical Affairs teams need to amplify their voice on social media channels – or lose out.
More Patients and Medical Articles
Patients and Medical
Optimizing patient Engagement in Trials
The importance of involving the patient at all stages of trials post-pandemic has never been clearer
Patients and Medical
Fixing the broken patient search experience
There’s opportunity as well as danger in the billion healthcare searches made every day. Why isn’t pharma tuning in?
Patients and Medical
The value in measuring the patient experience
Pharma can improve outcomes, products and HCP relationships using technology to capture patients’ day-to-day experience of their disease
Access and Evidence
Bringing innovation to rare disease patients in Europe
Johanna Friedl-Naderer, President, Europe, Canada & Partner Markets, Biogen on how collaboration between governments and industry can lead to better patient outcomes.
Access and Evidence
#Icare4Rare campaign launches to raise awareness ahead of Rare Disease Week 2021
To help raise awareness of rare disease, Reuters Events, Biogen and EU40 have collaborated to launch the #Icare4rare campaign to give prominence to Rare Disease Week 2021
Patients and Medical
Better research through patient insights
AstraZeneca’s innovations in chronic kidney disease are pointing the way to new ways of involving patients and RWE to drive new insights and better outcomes
Patients and Medical
Building a health equity culture
Health inequities, often a legacy of racism, lie heavy on the healthcare sector in the US and beyond. Fixing the problem will require long-term effort on multiple fronts
Patients and Medical
Digital companions: helping improve patient treatment journeys
The virtual health explosion isn't going away. This just at the start of an era of digital enhancement
Patients and Medical
Racially diverse clinical trials: A new patient-led legacy takes root
Attempts to make trials more diverse aren’t working. To overcome far-reaching inequality and deep distrust, pharma must be educated by, as well as educate, under-served communities